GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » YIFAN PHARMACEUTICAL CO LTD (SZSE:002019) » Definitions » Net Income (Continuing Operations)

YIFAN PHARMACEUTICAL CO (SZSE:002019) Net Income (Continuing Operations) : ¥-812 Mil (TTM As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is YIFAN PHARMACEUTICAL CO Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. YIFAN PHARMACEUTICAL CO's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was ¥118 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-812 Mil.


YIFAN PHARMACEUTICAL CO Net Income (Continuing Operations) Historical Data

The historical data trend for YIFAN PHARMACEUTICAL CO's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

YIFAN PHARMACEUTICAL CO Net Income (Continuing Operations) Chart

YIFAN PHARMACEUTICAL CO Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 873.12 931.39 242.21 127.09 -885.65

YIFAN PHARMACEUTICAL CO Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.99 40.68 16.43 -986.75 117.55

YIFAN PHARMACEUTICAL CO Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-812 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


YIFAN PHARMACEUTICAL CO  (SZSE:002019) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


YIFAN PHARMACEUTICAL CO Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of YIFAN PHARMACEUTICAL CO's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


YIFAN PHARMACEUTICAL CO (SZSE:002019) Business Description

Traded in Other Exchanges
N/A
Address
No. 50 Qinshan, Jincheng, Lin'an Economic Development Zone, Hangzhou, Zhejiang, CHN, 311300
YIFAN PHARMACEUTICAL CO LTD is a China-based company engaged in pharmaceutical innovation and manufacturing. The company focuses its activities on key areas like macromolecular biologics, high-value pharmaceuticals, and differentiated traditional Chinese medicines. The products of the company are F-627 for Neutropenia and Parkinson's disease, F-652 for acute alcoholic hepatitis, GvHD and acute pancreatitis and F-899 for growth deficiency. The company's products are sold in China and internationally.
Executives
Ye Yi Qun Director
Zhang Da Wei Executives
Geng Yu Hong Executives
Feng De Qi Directors, Directors, and Executives
Zhou Ben Yu Director
Lin Xing Directors, executives
Yu Hai Xia Executives
Cheng Xian Feng Directors, executives
Xu Guo Han Supervisors
Cao Shi Mei Director
Lin Guan Yu Director
Zhang Lian Chun Executives
Guo Xin Fu Director
Zheng Shi Ming Supervisors
Yin Hang Hua Executives

YIFAN PHARMACEUTICAL CO (SZSE:002019) Headlines

No Headlines